Physician profile
Mark V Graves
NPI 1679647291
$1,768.46
in general payments reported to CMS, 2019-2025
9 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $111 · 2021: $281 · 2022: $310 · 2023: $290 · 2024: $395 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $677.59 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $334.72 | 2019-2024 | Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $255.76 | 2022-2025 | Infuse, Biotrue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $118.71 | 2025 | |
| Abbvie INC. | $113.48 | 2022 | |
| Harrow Eye, LLC | $108.60 | 2024 | Vevye |
| Shire North American Group INC | $21.35 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.